The pso Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the pso Hub cannot guarantee the accuracy of translated content. The pso and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB: For educational content and news updates.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View pso content recommended for you
PSO-TARGET: A new tool to assess therapeutic expectations of patients treated with biologics
Treatment goals in psoriasis can differ between patients and physicians, and these differences can cause disparities in perceived achievement of treatment success.1 Therefore, there is a need for tools that can assist in shared treatment decision-making.1 A new tool, the PSO-TARGET grid, was conceived in a preliminary study of 45 patients, 3 dermatologists, and 1 psychologist.1 The grid comprises 12 therapeutic goals split into 4 categories (physical, subjective, relational/social, and therapeutic). The multicenter, observational, prospective PSO-TARGET study compared the PSO-TARGET grid to the conventionally used DLQI tool in 143 adult patients with moderate-to-severe plaque psoriasis treated with brodalumab. Results were published by Reguiai et al.1 in Dermatology and Therapy. |
Key learnings |
| The most chosen goals in the PSO-TARGET grid were physical (39.4%). Physicians were unable to correctly identify their patients' chosen therapeutic goal in >50% of cases, highlighting gaps in understanding patient priorities. |
| Patients who achieved their PSO-TARGET goal but reported a DLQI >1 had higher baseline PASI and DLQI scores and were more likely to have hard-to-treat locations (p = 0.004), demonstrating that DLQI may not always capture treatment satisfaction or dissatisfaction. |
| >85% of patients maintained their therapeutic goal choice at Week 12/16 follow-up. Satisfaction with achieving the goal after brodalumab treatment increased from 82.2% at 12/16 weeks to 88.8% at 52 weeks. |
| This study underscores the need for patient-centric tools in dermatology to enhance treatment personalization and shared decision-making in psoriasis care. The PSO-TARGET tool can help align treatment strategies with patient expectations, potentially improving treatment adherence and satisfaction. |
Abbreviations: DLQI, dermatology life quality index; PASI, psoriasis area and severity index.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
